Related Experiment Video

Updated: Dec 11, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.4K

Updates on community acquired pneumonia management in the ICU

Girish B Nair1, Michael S Niederman2

  • 1Oakland University William Beaumont School of Medicine, Royal Oak, MI, USA.

Pharmacology & Therapeutics
|August 18, 2020
PubMed

Insights

Streptococcus pneumoniae remains a leading cause of severe community-acquired pneumonia (SCAP). This review covers SCAP risk factors, diagnosis, and treatment strategies, emphasizing timely antibiotic use to reduce mortality and combat resistance.

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Microbiology
  • Critical Care Medicine

Background:

  • Severe community-acquired pneumonia (SCAP) poses a significant global health challenge, with Streptococcus pneumoniae identified as a primary bacterial culprit.
  • Despite advancements in rapid diagnostics and molecular testing for pathogen identification, intensive care unit (ICU) mortality rates for SCAP patients remain high.
  • Current guidelines from the American Thoracic Society and Infectious Diseases Society of America aim to standardize SCAP management.

Purpose of the Study:

  • To review and synthesize current knowledge on SCAP, focusing on risk factors, microbiological aspects, and clinical decision-making.
  • To highlight the importance of appropriate and timely antibiotic therapy in reducing mortality and preventing antimicrobial resistance in SCAP.
  • To discuss novel antibiotic options for patients with SCAP who are intolerant to standard treatments or infected with drug-resistant pathogens.

Main Methods:

  • This is a review article, synthesizing existing literature and clinical guidelines.
  • Focuses on risk stratification, etiological diagnosis, and therapeutic strategies for SCAP.
  • Examines evidence regarding antibiotic selection, duration, and the role of novel agents.

Main Results:

  • Streptococcus pneumoniae is the most common cause of SCAP, contributing to high ICU mortality.
  • Timely, appropriate antibiotic coverage is crucial for improving outcomes and mitigating drug resistance.
  • Novel antibiotics offer expanded therapeutic options for complex or resistant SCAP cases.

Conclusions:

  • Effective management of SCAP requires a comprehensive approach, including accurate risk assessment and pathogen identification.
  • Adherence to updated clinical guidelines and judicious antibiotic use are paramount in reducing SCAP-related mortality and combating resistance.
  • Further research into novel therapeutic strategies is essential to address the challenges posed by drug-resistant pathogens in SCAP.
Keywords:
ATS/IDSA CAP guidelinesCAP severity assessment scoresNew antibioticsSevere community acquired pneumoniaSite of care

More Related Videos

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

3.0K
A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.0K

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
638
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.1K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
585
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
677
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
340
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
187